Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel Sells 36,256 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 36,256 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the completion of the sale, the executive vice president now directly owns 735,074 shares of the company’s stock, valued at approximately $8,394,545.08. This represents a 4.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total value of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Stock Performance

Shares of Alphatec stock opened at $12.14 on Wednesday. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The company has a market capitalization of $1.72 billion, a PE ratio of -9.48 and a beta of 1.43. The stock’s fifty day simple moving average is $10.20 and its 200 day simple moving average is $8.08.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Needham & Company LLC raised their target price on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Barclays lifted their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Institutional Investors Weigh In On Alphatec

A number of hedge funds have recently modified their holdings of ATEC. R Squared Ltd bought a new stake in Alphatec during the 4th quarter worth approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in shares of Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares during the period. Newton One Investments LLC bought a new stake in shares of Alphatec during the fourth quarter worth $50,000. XTX Topco Ltd bought a new stake in Alphatec in the 3rd quarter valued at $69,000. Finally, Ballentine Partners LLC acquired a new position in Alphatec in the 4th quarter worth $120,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.